Nuzenio

Silexion Therapeutics

Silexion Therapeutics news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 13 latest news signals 10 publisher sources 100/100 entity strength

Latest news

Silexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancers - BitgetBitget · Sun, 09 Aug 2026 13:24:56 GMTSilexion Therapeutics (NASDAQ: SLXN) files S-1 for best-efforts unit sale - Stock TitanStock Titan · Fri, 07 Aug 2026 22:52:53 GMTTop Silexion Therapeutics Corp - Warrant (SLXNW) Competitors 2026 - MarketBeatMarketBeat · Thu, 06 Aug 2026 20:42:27 GMTSilexion to present preclinical data on SIL-204 at GI cancer event - Investing.comInvesting.com · Tue, 04 Aug 2026 15:03:49 GMTSilexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers - Yahoo FinanceYahoo Finance · Tue, 04 Aug 2026 13:15:00 GMTSilexion Therapeutics restores Nasdaq audit committee compliance with new appointment - TradingViewTradingView · Mon, 03 Aug 2026 13:33:01 GMTAmnon Peled resigns from Silexion Therapeutics board effective Aug 1, 2026 - TradingViewTradingView · Fri, 31 Jul 2026 07:00:00 GMTSilexion Therapeutics Corp Warrant (SLXNW) Holds Near Par After Modest Decline - Overvalued Signals - dars.gov.etdars.gov.et · Thu, 30 Jul 2026 22:33:16 GMT

Timeline

Sun, 09 Aug 2026 13:24:56 GMTSilexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancers - Bitget
Fri, 07 Aug 2026 22:52:53 GMTSilexion Therapeutics (NASDAQ: SLXN) files S-1 for best-efforts unit sale - Stock Titan
Thu, 06 Aug 2026 20:42:27 GMTTop Silexion Therapeutics Corp - Warrant (SLXNW) Competitors 2026 - MarketBeat
Tue, 04 Aug 2026 15:03:49 GMTSilexion to present preclinical data on SIL-204 at GI cancer event - Investing.com
Tue, 04 Aug 2026 13:15:00 GMTSilexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers - Yahoo Finance
Mon, 03 Aug 2026 13:33:01 GMTSilexion Therapeutics restores Nasdaq audit committee compliance with new appointment - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Silexion Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

10 distinct publisher/source names are currently connected to this entity page.